Assertion: harpoon | /r/CapableOf | dose first patient
Facets:
Source sentences:
text: In April, Harpoon advanced its second TriTAC, HPN536, a mesothelin-targeting T cell engager, into the clinic and dosed the first patient in a Phase 1/2a clinical trial for ovarian and other mesothelin-expressing solid tumors.